Despite being used for decades as a primary treatment for acute gout, optimal colchicine dosing has not been systematically evaluated. This is potentially important, as higher doses of colchicine can frequently be associated with the undesired consequence of severe diarrhea and gastrointestinal distress.
Reactivation of latent tuberculosis is a recognized risk of TNF inhibitor use. While there has been circumstantial evidence of greater risk with the monoclonal antibody TNF inhibitors (e.g. infliximab and adalimumab) compared with decoy receptor TNF inhibitors (e.g. etanercept), there have been few direct comparisons. Here, Dixon et al (Ann Rheum Dis 2010; 69: 522-528) […]
Limited data have suggested that the selective-serotonin reuptake inhibitors (SSRIs) may have anti-inflammatory properties in addition to their antidepressant effects. Here, Sacre et al (Arthritis Rheum 2010; 62(43): 683) explore the mechanisms of two SSRIs (fluoxetine and citalopram) in models of experimental arthritis. Methods Inflammation was induced in the paws of male DBA/1 mice by […]
Treatment with rituximab, a monoclonal antibody targeting CD20+ B cells, could adversely affect immunization responses by dampening the antibody response from new vaccination or reducing pre-formed antibody from prior vaccination. However, little systematic investigation of immunization responses has been undertaken. Here, two studies concurrently published in Arthritis & Rheumatism explore responses after influenza vaccination (van […]
Measuring the amount of polyglutamated methotrexate within red blood cells has been proposed as an objective method of tracking medication response and predicting drug toxicity. However, there are only limited data evaluating this method. Here, Stamp et al (Arthritis Rheum 2010; 62(2)): 359) cross-sectionally explore the associations of RBC polyglutamated methotrexate levels with disease activity […]
Injections of platelet-rich plasma are becoming increasingly applied in clinical practice for a number of indications, yet little high-quality systematic study of efficacy has been conducted. Platelets are a source of growth factors involved in tissue repair, supporting their application in injuries and wound healing. Here, de Vos et al (JAMA 2010; 303(2): 144) report […]
On January 8, 2010, the U.S. Food and Drug Administration approved tocilizumab (to be marketed under the trade name of Actemra) for the treatment of patients with moderate to severe rheumatoid arthritis who have had inadequate clinical responses to treatment with TNF inhibitors. Tocilizumab is a humanized monoclonal antibody directed against the receptor for IL-6, […]
Rheumatoid arthritis disease activity tends to improve during pregnancy, even when disease modifying agents are stopped. However, a minority of women with rheumatoid arthritis will continue to have active disease during pregnancy, and may require additional immunosuppression. Prior studies have yielded conflicting reports on the influence of active disease during pregnancy. Here, de Man et […]
While most observational studies have not demonstrated an increase in malignancy independently associated with TNF inhibitor use, a meta-analysis of short-term clinical trials data suggested an increase in malignancy risk occurring within months of initiating therapy with monoclonal antibodies directed against TNF-α (infliximab and adalimumab).
Estimates of the prevalence of psoriatic arthritis among individuals with skin psoriasis have varied in the literature from between 2% to more than 40%, depending on the method of ascertainment and case definition used to define psoriatic arthritis.